NCT01689584 COsegregation of VARiants in Panel of Genes
| NCT ID | NCT01689584 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institut Curie |
| Condition | Gene Mutation-Related Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 11,000 participants |
| Start Date | 2012-07-02 |
| Primary Completion | 2037-07-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 11,000 participants in total. It began in 2012-07-02 with a primary completion date of 2037-07-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of the COVAR project is to achieve reliable classification of as many variants of interest as possible from the French OncoGenetics Database (FrOG, https://frog-db.fr/) in order to use them for the genetic counseling. The results obtained through this study will have a major impact on clinical management of the patients and their families conducting in some cases to propose a prophylactic surgery.
Eligibility Criteria
Inclusion Criteria: Index cases: * A person carrying a variant of interest in a gene analyzed in a diagnostic setting by one of the laboratories within the Genetics and Cancer Group (GGC)-Unicancer network, classified as class 3, 4 or hypomorphic class 5, and selected by the national expert group for the gene concerned. * Age ≥ 18 years. * Signed written inform consent "index case" Related parties: * Any relative of an index case with cancer * Any relative without cancer related to an index case, selected by the investigators, according to family structure and degree of related compared to the index case * For class 4 and hypomorphic class 5 variants; relatives currently undergoing analysis or having already obtained a test result for the variant of interest as part of clinical care. * Age ≥ 18 years * Information and signature of the informed consent "selected relatives" Exclusion Criteria: * Minors * Persons deprived of liberty or under guardianship (including curators). * Absence of signed written inform consent
Contact & Investigator
Chrystelle COLAS, MD, PhD
STUDY CHAIR
Institut Curie
Frequently Asked Questions
Who can join the NCT01689584 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Gene Mutation-Related Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT01689584 currently recruiting?
Yes, NCT01689584 is actively recruiting participants. Contact the research team at sandrine.caputo@curie.fr for enrollment information.
Where is the NCT01689584 trial being conducted?
This trial is being conducted at Bastia, France, Saint-Cloud, France, Amiens, France, Angers, France and 11 additional locations.
Who is sponsoring the NCT01689584 clinical trial?
NCT01689584 is sponsored by Institut Curie. The principal investigator is Chrystelle COLAS, MD, PhD at Institut Curie. The trial plans to enroll 11,000 participants.
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.